ALCAM and melanoma: The value of ALCAM as unfavorable prognosis marker is reported in colon [8], pancreas [33], urinary bladder [35], breast [34, 36], and endometrial [37] tumors, melanoma [38], and other types of malignancies [39], while the association between ALCAM strong expression and a favorable outcome is recorded in prostate cancer [40, 41].